First Biologic Drug in the Treatment of RAS Wild-Type Metastatic Colorectal Cancer: Anti-EGFR or Bevacizumab? Results From a Meta-Analysis

Introduction: We performed a meta-analysis in order to analyze and quantify the effect on survival of starting therapy in RAS wild-type (wt) metastatic colorectal cancer (mCRC) patients with anti-EGFR agents or bevacizumab. Patients and Methods: Randomized, phase II or III, clinical trials reporting...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Pharmacol
Main Authors: Ottaiano, Alessandro, De Stefano, Alfonso, Capozzi, Monica, Nappi, Anna, De Divitiis, Chiara, Romano, Carmela, Silvestro, Lucrezia, Cassata, Antonino, Casaretti, Rossana, Tafuto, Salvatore, Caraglia, Michele, Berretta, Massimiliano, Nasti, Guglielmo, Avallone, Antonio
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2018
Assuntos:
Pharmacology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5943532/
https://ncbi.nlm.nih.gov/pubmed/29773991
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2018.00441
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares